Buske C - Search Results

1

TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition.

Bamezai S, Demir D, Pulikkottil AJ, Ciccarone F, Fischbein E, Sinha A, Borga C, Te Kronnie G, Meyer LH, Mohr F, Götze M, Caiafa P, Debatin KM, Döhner K, Döhner H, González-Menéndez I, Quintanilla-Fend L, Herold T, Jeremias I, Feuring-Buske M, Buske C, Rawat VPS. Bamezai S, et al. Among authors: buske c. Leukemia. 2021 Feb;35(2):389-403. doi: 10.1038/s41375-020-0864-3. Epub 2020 May 15. Leukemia. 2021. PMID: 32409690

2

TGF-beta inhibits growth and induces apoptosis in leukemic B cell precursors.

Buske C, Becker D, Feuring-Buske M, Hannig H, Wulf G, Schäfer C, Hiddemann W, Wörmann B. Buske C, et al. Leukemia. 1997 Mar;11(3):386-92. doi: 10.1038/sj.leu.2400586. Leukemia. 1997. PMID: 9067578

3

In vitro activation of low-grade non-Hodgkin's lymphoma by murine fibroblasts, IL-4, anti-CD40 antibodies and the soluble CD40 ligand.

Buske C, Twiling A, Gogowski G, Schreiber K, Feuring-Buske M, Wulf GG, Hiddemann W, Wörmann B. Buske C, et al. Leukemia. 1997 Nov;11(11):1862-7. doi: 10.1038/sj.leu.2400822. Leukemia. 1997. PMID: 9369419

4

TGF-beta and its receptor complex in leukemic B-cell precursors.

Buske C, Becker D, Feuring-Buske M, Hannig H, Griesinger F, Hiddemann W, Wörmann B. Buske C, et al. Exp Hematol. 1998 Nov;26(12):1155-61. Exp Hematol. 1998. PMID: 9808055

5

Clonal chromosomal abnormalities in the stem cell compartment of patients with acute myeloid leukemia in morphological complete remission.

Feuring-Buske M, Haase D, Buske C, Hiddemann W, Wörmann B. Feuring-Buske M, et al. Among authors: buske c. Leukemia. 1999 Mar;13(3):386-92. doi: 10.1038/sj.leu.2401300. Leukemia. 1999. PMID: 10086729

6

[New developments in therapy of non-Hodgkin lymphomas with monoclonal antibodies].

Buske C, Feuring-Buske M, Unterhalt M, Hiddemann W. Buske C, et al. Dtsch Med Wochenschr. 1999 Jul 9;124(27):842-7. doi: 10.1055/s-2007-1024429. Dtsch Med Wochenschr. 1999. PMID: 10432945 Review. German. No abstract available.

7

Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: emerging concepts of a tumour-targeted strategy.

Buske C, Feuring-Buske M, Unterhalt M, Hiddemann W. Buske C, et al. Eur J Cancer. 1999 Apr;35(4):549-57. doi: 10.1016/s0959-8049(98)00420-1. Eur J Cancer. 1999. PMID: 10492626 Review.

8

Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma.

Feuring-Buske M, Buske C, Unterhalt M, Hiddemann W. Feuring-Buske M, et al. Among authors: buske c. Ann Hematol. 2000 Apr;79(4):167-74. doi: 10.1007/s002770050575. Ann Hematol. 2000. PMID: 10834503 Review.

9

[Pathogenesis and biology of leukemias].

Feuring-Buske M, Hiddemann W, Buske C. Feuring-Buske M, et al. Among authors: buske c. Internist (Berl). 2002 Oct;43(10):1179-89. doi: 10.1007/s00108-002-0701-y. Internist (Berl). 2002. PMID: 12524900 Review. German. No abstract available.

10

Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia.

Rawat VP, Cusan M, Deshpande A, Hiddemann W, Quintanilla-Martinez L, Humphries RK, Bohlander SK, Feuring-Buske M, Buske C. Rawat VP, et al. Among authors: buske c. Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):817-22. doi: 10.1073/pnas.0305555101. Epub 2004 Jan 12. Proc Natl Acad Sci U S A. 2004. PMID: 14718672 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

276 results

Search Page